From KDIGO 2012 towards KDIGO 2021 in idiopathic membranous nephropathy guidelines: what has changed over the last 10 years?
Authors:
Open Access
- 30 November 2022
- journal article
- review article
- Published by Oxford University Press (OUP) in Journal Of Nephrology
- Vol. 36 (2) , 551-561
Abstract
The recommendations in the Kidney Disease: Improving Global Outcomes (KDIGO) 2021 guidelines regarding Idiopathic Membranous Nephropathy (IMN) management include significant changes as compared to those published in 2012. According to the recent guidelines, a biopsy is not always needed for IMN diagnosis; since diagnosis can be allowed for by the detection of circulating antibodies against the M-type transmembrane phospholipase A2 receptor (anti-PLA2R). Moreover, alterations in anti-PLA2R concentrations, along with other serum and urinary markers, may guide further follow-up. The findings of numerous recent studies which compared different immunosuppressive treatments resulted in substantial changes in treatment indications in the KDIGO 2021 guidelines, suggesting the stratification of patients into four risk categories. The definition of resistant cases and relapses was likewise modified. All the above will lead to a more granular and personalized approach, whose results need to be tested over time. In this commentary, we discuss the changes in the 2012 and 2021 guidelines, adding information from the most recent literature. GraphicalKeywords
Funding Information
- Aristotle University of Thessaloniki
- Aristotle University of Thessaloniki
This publication has 42 references indexed in Scilit:
- Immunosuppression for progressive membranous nephropathy: a UK randomised controlled trialThe Lancet, 2013
- Low- and high-molecular-weight urinary proteins as predictors of response to rituximab in patients with membranous nephropathy: a prospective studyNephrology Dialysis Transplantation, 2012
- Immunosuppressive Treatment for Nephrotic Idiopathic Membranous Nephropathy: A Meta-Analysis Based on Chinese AdultsPLOS ONE, 2012
- Is the Antiproteinuric Effect of Cyclosporine A Independent of Its Immunosuppressive Function in T Cells?International Journal of Nephrology, 2012
- Cyclosporine: A ReviewJournal of Transplantation, 2012
- Calcineurin Inhibitors: Short-Term Friend, Long-Term Foe?Clinical Pharmacology & Therapeutics, 2011
- Tacrolimus Combined With Corticosteroids in Treatment of Nephrotic Idiopathic Membranous Nephropathy: A Multicenter Randomized Controlled TrialThe American Journal of the Medical Sciences, 2010
- Experimental models of membranous nephropathyDrug Discovery Today: Disease Models, 2010
- Cyclophosphamide pharmacokinetics and dose requirements in patients with renal insufficiencyKidney International, 2002
- Preserving Renal Function in Patients with Membranous Nephropathy: Daily Oral Chlorambucil Compared with Intermittent Monthly Pulses of CyclophosphamideAnnals of Internal Medicine, 1994